Men with Advanced Prostate Cancer Should Consider Genetic Testing

In the light of recent discoveries (recently posted on this website) that some advanced prostate cancer patients harbor specific genetic mutations, a recent study summarized in the July 7th National Library of Medicine MedLine Plus suggested that testing for inherited abnormalities in DNA repair genes could provide patients and family members important information about their health and cancer risk. The research team led by Dr. Michael Walsh, a geneticist and pediatric oncologist at Memorial Sloan Kettering Cancer Center in New York states that “historically, the main benefit of identifying cancer-causing mutations has been prevention and early detection in families. Now we can use inherited genomic information to target treatment, with specific therapies shown to be effective in those with specific genomic subsets of prostate cancer.”

The research team found a link between advanced prostate cancer and mutations in DNA repair genes. The mutations occur far more often in men with advanced disease than in those with prostate cancer that hasn’t spread, the study authors said. In addition, men with the abnormal repair genes are more likely to have close relatives with cancers other than prostate cancer compared to men without the mutations. These findings could help identify families that are at high risk for cancer and help prevent it in future generations, the researchers said.


Three weeks ago, a good friend called me from his vacation to say his PSA had jumped from 4-5 to 8-9 within a few months. My friend was a Christian who definitely had a personal relationship with God through Jesus Christ. But he was very anxious as we probably all would be or have been at one time. He and I prayed and after a few days of consideration, my friend obtained an ultrasound-guided biopsy. Fortunately in his case, his 12 samples all came back negative for prostate cancer. But  his experience reminded me again of the following devotional entitled “Anxiety” from Dr. Charles Stanley of In Touch Ministries which could apply at some time or other to anyone with health problems including cancer. The scripture text was Matthew 6:25, “do not worry about your life”.

“Has anxiety become a way of life for you? Are you living in a constant state of uncertainty and worry? Fear will arise whenever you respond to a problem or troubling situation on your own-without going to God first and seeking His help and power.  The Lord gives you the gift of free will-you can choose what you do, how you feel, what you think about, and even how you’ll respond when faced with a problem.” Personally, anxiety is a signal that I must pray. Peace is a sign that I have given it all over to God. I am to pray until I have God’s peace according to Philippians 4:6-7 (‘let your requests be made known to God and the peace of God which passes all understanding shall keep your hearts and mind through Christ Jesus.’)

With this in mind, the Father may allow an overwhelming situation to arise in your life in order to develop and strengthen your faith, mature you spiritually, or to change a bad habit or negative attitude. Through your circumstances, He gives you the opportunity to seek Him, trust Him, obey Him and cast your care into His able hands. Therefore, understand your anxiety is an indication that you need God. Every time you sense fear rising up within you, go to your all-powerful, infinitely-wise Father. And give Him thanks that He is at work, teaching you to trust Him more, obey Him faithfully, and receive more of His blessings. A sample prayer could be ‘Father, I won’t be anxious for You are with me. Thank you for releasing me from this bondage of fear, amen.’ In His presence….find freedom from anxiety.”

If you are not sure of your relationship with God, see the following link.

High Prostate Cancer Risk Linked to Inherited Mutations in DNA-Repair Genes.

Mutations in DNA-repair genes, including the breast cancer genes BRCA1 and BRCA2, are involved in an inherited high risk of prostate cancer and, potentially, the risk of an aggressive cancer, according to researchers at Fred Hutchinson Cancer Research Center and the University of Washington.

The study entitled, “Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer”,  published in The New England Journal of Medicine, found the mutations in about 12 percent of men with the cancer — and found that men with metastatic prostate cancer were five times more likely than most people to have these DNA-repair gene mutations. Results suggest that screening for such mutations could help tailor their treatment and encourage family members to consider their own cancer risk.

Because BRCA1 and BRCA2 mutations have long been associated only with breast and ovarian cancers, it was thought that the mutations only affected women.

“I think these data really suggest that we need to engage men in discussions about genetics, where it has not been central before,” Dr. Heather Cheng, a Fred Hutchinson and University of Washington prostate cancer researcher.

The team analyzed 20 DNA-repair genes in metastatic prostate tumors and healthy tissues of 692 men. They found that 16 of the genes were mutated in both malignant and healthy cells in 12 percent of the metastatic cancer patients — much higher than researchers ever suspected, said first author Dr. Colin Pritchard.

“The implications are big in terms of intercepting and preventing a cancer because [carriers of these mutations] are at high risk,” said Dr. Pete Nelson, a Fred Hutch prostate cancer researcher and senior author on the study.

The findings are also important because men with advanced prostate cancer who have the mutations in DNA-repair genes could be treated with PARP inhibitors or platinum chemotherapy, which is commonly used in breast cancer patients. Although not yet approved for prostate cancer treatment, the treatments are on fast-track review by the U.S. Food and Drug Administration.

“For men with metastatic disease who are found to have these mutations, there are very clear treatment implications that would not otherwise be considered for prostate cancer. It would essentially expand [the patients’] toolbox of treatments,” Cheng said.

The authors concluded that it may be of interest to routinely examine all men with metastatic prostate cancer for the presence of germline mutations in DNA-repair genes. Future work by investigators will focus on determining which mutations predispose patients to the most aggressive type of prostate cancer.

The researchers hope the findings will land the screening in National Comprehensive Cancer Network guidelines — with future coverage by insurance companies.

Some of this information above also appeared in the blog dated July 28th, 2016. Information on PARP inhibitors under development can be found in the post dated November 30th, 2015.


Custersin Fails to Improve Survival in Advanced Prostate Cancer Patients

The Phase 3 AFFINITY Trial failed to met its primary endpoint of significantly improved overall survival in men with metastatic castrate-resistant prostate cancer (CRPC) being treated with custirsen, the therapy’s maker, OncoGenex announced.

The international, randomized, open-label study evaluated 634 men with CRPC whose disease had progressed despite treatment with docetaxel (taxotere). In the trial, patients received weekly doses of cabazitaxel or prednisone with or without the addition of custirsen (OGX-011). Treatment continued until disease progression, unacceptable toxicity or completion of 10 cycles.

Results showed that adding custirsen did not provide significant overall survival benefit. Adverse events were consistent with those observed in previous trials of custirsen in men with CRPC.

Custirsen is designed to inhibit the production of clusterin, a protein involved in cancer cell survival and treatment resistance. Clusterin is upregulated in tumor cells in response to treatment interventions such as chemotherapy, hormone ablation, and radiation therapy, and is overexpressed in a number of cancers, including prostate cancer.

Increased clusterin production is associated with faster rates of cancer progression, treatment resistance, and shorter survival duration. By inhibiting clusterin, custirsen aims to alter tumor dynamics, slowing tumor growth and resistance to other treatments to amplify the benefits of therapy, including survival.

For more information, see the August 24th e mail issue of Prostate Cancer News Today.


More News and Video on Vitamin D and Prostate Cancer

To understand better the benefits of vitamin D, watch this video shared by the Prostate Cancer Research Institute where Dr. Charles Myers, a medical oncologist and prostate cancer patient himself, talks about the use of vitamin D, how patients can benefit from it and how its deficiency can worsen patients’ health condition. In this 2-minute video, Dr. Myers always monitors the 25-hydroxy vitamin D levels of his patients and supplements them as needed with up to 5000-7000 units (IU) /day to achieve an optimum Vitamin D range of 40-80 nanograms/mL. It should be noted that vitamin D is a fat-soluble vitamin and can be problematic if taken in large excess. It is best absorbed when taken with the highest fat-containing meal of the day. Supplementation and dosage should be discussed with your health care provider.

In an accompanying study, researchers at the Medical University of South Carolina presented a clinical study entitled “Vitamin D in the prevention and treatment of cancer.”  In this study, Dr. Bruce Hollis shows that supplementation with vitamin D (2,000-4,000 IU daily) can have a significant impact on disease progression, with the ability to alter molecular and biochemical pathways, slowing or even decreasing the development of less aggressive, or low-grade, prostate tumors without undergoing surgery or radiation. It was concluded that vitamin D seems to be specifically targeting tumor inflammation occurring mainly in the prostate gland, arresting lower-grade prostate cancers from becoming aggressive.

Previously on this Godandprostate website, posts discussing the relationship of vitamin D to prostate cancer have been posted on July 14, 2016, May 5th, 2016, Jan 21, 2015 and July 17th, 2014.